Table 1.
Demographic Characteristics of Study Participants
| |
HIV− |
HIV+ |
|
||
|---|---|---|---|---|---|
| Variable | MC− (n=41) | MC+ (n=37) | MC− (n=59) | MC+ (n=64) | p |
| Age (years) | 42±6 | 44±8 | 42±7 | 43±7 | 0.739 |
| Male, n (%) | 35 (85) | 33 (89) | 45 (76) | 53 (83) | 0.433 |
| African-American, n (%) | 14 (34) | 7 (19) | 31 (53) | 29 (45) | 0.005 |
| Other nonwhite, n (%) | 0 (0) | 0 (0) | 0 (0) | 2 (3) | |
| CD4 (cells/μl) | N/A | N/A | 515±206 | 537±260 | — |
| Median viral load (copies/ml) | N/A | N/A | UD (0–33,872) | UD (0–48,600) | — |
| Median HIV duration (months) | N/A | N/A | 133 (14–262) | 121 (23–272) | — |
| Median cART use (months) | N/A | N/A | 71 (3–246) | 73 (4–237) | — |
| Current tobacco use, n (%) | 10 (24) | 10 (27) | 25 (43) | 14 (22) | 0.064 |
| Antiretroviral therapy, n (%) | |||||
| NRTI | N/A | N/A | 56 (95) | 60 (94) | — |
| NNRTI | N/A | N/A | 26 (44) | 29 (45) | — |
| PI | N/A | N/A | 32 (54) | 39 (61) | — |
| Fusion | NA | NA | 0 (0) | 2 (3) | — |
| Medical therapy, n (%) | |||||
| HTN | 6 (15) | 16 (43) | 4 (7) | 15 (23) | <0.001 |
| Lipid lowering | 3 (7) | 10 (27) | 2 (3) | 16 (25) | <0.001 |
HIV, human immunodeficiency virus; MC, metabolic complications; cART, combined antiretroviral therapy; UD, undetectable<400 copies/ml; BMI, body mass index; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Fusion, fusion inhibitor; HTN, hypertension.